Want to see TECX full AI Analyst Report?
Tectonic Therapeutic (TECX) AI Stock Analysis
Tectonic Therapeutic
(NASDAQ:TECX)
The score is held down primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting these, the balance sheet is a clear strength with very low leverage, and a recent positive clinical/regulatory update (Phase 1a results and Fast Track) provides a notable but still early-stage catalyst.
Tectonic Therapeutic (TECX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $386.69M
- Dividend Yield
- ―
- Average Volume (3M)
- 219.08K
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 1.33
- Revenue Growth
- ―
- EPS Growth
- -13.09%
- Country
- US
- Employees
- 60
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Tectonic Therapeutic Business Overview & Revenue Model
Company Description
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors...
How the Company Makes Money
null
Tectonic Therapeutic Financial Statement Overview
Summary
Overall financial profile is mixed: a very strong, lightly levered balance sheet (debt-to-equity ~0.02) is offset by a pre-revenue model with widening losses (net loss -$85.8M TTM) and accelerating operating/free cash burn (~-$90.6M/-$90.9M TTM). Funding durability is the key financial swing factor.
Income Statement
18Very NegativeBalance Sheet
74PositiveCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -83.79M | -71.48M | -56.23M | -41.19M | -31.03M | -8.12M |
| Net Income | -85.79M | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M |
Balance Sheet | ||||||
| Total Assets | 237.03M | 261.04M | 152.91M | 39.40M | 47.21M | 32.88M |
| Cash, Cash Equivalents and Short-Term Investments | 227.07M | 253.80M | 141.24M | 28.77M | 35.97M | 28.06M |
| Total Debt | 4.40M | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M |
| Total Liabilities | 13.19M | 9.71M | 12.13M | 124.03M | 92.86M | 47.84M |
| Stockholders Equity | 223.85M | 251.33M | 140.78M | -84.64M | -45.65M | -14.96M |
Cash Flow | ||||||
| Free Cash Flow | -72.45M | -60.29M | -59.24M | -40.96M | -97.47M | -14.58M |
| Operating Cash Flow | -72.14M | -60.08M | -59.08M | -40.68M | -97.21M | -12.45M |
| Investing Cash Flow | -216.00K | -138.00K | -156.00K | -279.00K | -267.00K | -2.12M |
| Financing Cash Flow | 11.93M | 173.35M | 171.71M | 33.75M | 262.00K | 41.42M |
Tectonic Therapeutic Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECX, the sentiment is Negative. The current price of 18.58 is below the 20-day moving average (MA) of 21.40, below the 50-day MA of 26.01, and below the 200-day MA of 28.08, indicating a bearish trend. The MACD of -1.50 indicates Negative momentum. The RSI at 30.77 is Neutral, neither overbought nor oversold. The STOCH value of 22.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECX.
Tectonic Therapeutic Risk Analysis
Tectonic Therapeutic disclosed 78 risk factors in its most recent earnings report. Tectonic Therapeutic reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskTectonic Therapeutic Peers Comparison
Overall Rating
CGEN65Neutral
MGNX47Neutral- TECX46Neutral
CTMX43Neutral
SRZN36Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CGEN | 65Neutral | $187.56M | 5.27 | 42.57% | ― | 234.18% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| MGNX | 47Neutral | $152.88M | -10.91 | -31.27% | ― | 1.32% | 59.94% |
| TECX | 46Neutral | $386.69M | -4.33 | -35.26% | ― | ― | -13.09% |
| CTMX | 43Neutral | $509.88M | -5.20 | -38.46% | ― | -87.03% | -179.91% |
| SRZN | 36Underperform | $341.32M | -0.71 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TECX | Tectonic Therapeutic Inc | 19.78 | 3.04 | 18.16% | |
| CGEN | Compugen | 1.98 | 0.37 | 22.98% | |
| MGNX | MacroGenics Inc | 2.40 | 0.95 | 65.52% | |
| CTMX | CytomX Therapeutics Inc. | 2.34 | -1.75 | -42.79% | |
| SRZN | Surrozen, Inc. | 29.04 | 16.45 | 130.66% | |
| AGMB | AgomAb Therapeutics NV ADR | 7.49 | -7.16 | -48.87% |
Tectonic Therapeutic Corporate Events
Tectonic Therapeutic reports positive Phase 1a TX2100 results
PositiveOn September 29, 2026, Tectonic Therapeutic reported favorable topline results from a Phase 1a first-in-human trial of TX2100 in 48 healthy volunteers, with single ascending doses administered intravenously and subcutaneously generally safe and well-...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 30, 2026